2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Combination Therapy, Therapy Sequence, Biological Therapies, Transplantation, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Diseases, Bone Marrow Failure Syndromes, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Registries, Study Population, Human, Adult, Pediatric, Young Adult
PAPER

4301 A multi-center retrospective analysis comparing haplo, MSD and MUD allo-hcts for BCR-ABL+ AML: A study from the ALWP of the EBMT

Lin Li, Maud Ngoya2, Yishan Ye, MD3, Ibrahim Yakoub-Agha4, Regis Peffault De Latour, MD, PhD5, Hakan Ozdogu, MD6, Jacques-Olivier Bay, MD7, Hunault-Berger Mathilde, MD, PhD8, Anne Huynh, MD9, Edouard Forcade, MD, PhD10, Jerome Cornillon, MD11, Mohsen Alzahrani Sr, MD12, Khalid Halahleh, MD13, Tsila Zuckerman I, MD14, Raffaella Cerretti, MD15, Matthias Stelljes16, Simona Piemontese, MD17, Giorgia Battipaglia18, Annalisa Ruggeri, MD19, Yi Luo20, Jimin Shi21, Yanmin Zhao, MD22, Mohamad Mohty, MD, PhD23, He Huang, MD, PhD24, Arnon Nagler I, MD25, Eolia Brissot, MD, PhD26
1 Bone Marrow Transplantation center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
2 EBMT Paris Office, Hôpital Saint Antoine 184, rue du faubourg Saint Antoine 75571 Paris cedex 12 - France, Paris, France
3 Bone Marrow Transplantation center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
4 CHU de Lille, Lille, France, Lille, France
5 Saint-Louis Hospital, BMT Unit, Paris, France
6 Baskent University Hospital, Adana, Turkey
7 CHU ESTAING, Clermont, France
8 CHRU, Angers, France
9 CHU - Institut Universitaire du Cancer Toulouse, Toulouse, France
10 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
11 Institut de Cancerologie Lucien Neuwirth, Saint Etienne, France
12 King Abdul - Aziz Medical City, Riyadh, Saudi Arabia
13 King Hussein Cancer Centre Adult BMT Program, Amman, Jordan
14 Rambam Medical Center, Haifa, Israel
15 Tor Vergata University of Rome, Rome, Italy
16 University of Muenster, Münster, Germany
17 Hematology and Bone Marrow Transplantation Unit San Raffaele Scientific Institute, Milano, Italy
18 Hematology and Bone Marrow Transplantation Unit, Department of Clinical Medicine and Surgery, University Federico II of Naples, Naples, Italy
19 Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
20 Bone Marrow Transplantation center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
21 Bone Marrow Transplantation center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
22 Bone Marrow Transplantation center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
23 EBMT Paris Office, Hôpital Saint Antoine 184, rue du faubourg Saint Antoine 75571 Paris cedex 12 - France, Paris, France
24 Bone Marrow Transplantation center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
25 Division of Hematology, Chaim Sheba Medical Center (Sheba Tel HaShomer City of Health), Ramat Gan, Israel
26 EBMT Paris Study Unit, Hôpital Saint Antoine, Paris, France

Background

BCR-ABL- positive acute myeloid leukemia (AML) is a rare, high-risk AML subtype associated with poor outcomes despite the incorporation of tyrosine kinase inhibitors. Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative option.

A previous study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT) demonstrated the feasibility and curative potential of allo-HCT in BCR-ABL-positive AML. However, recent advances in transplantion strategies, including widespread use of post-transplant cyclophosphamide (PTCy)-based graft-versus-host disease (GVHD) prophylaxis, , have expanded alternative donor options. The optimal donor type among haploidentical, matched sibling donor (MSD), and matched unrelated donor (MUD) transplantation in BCR-ABL-positive AML remains unclear. We conducted a multicenter retrospective study on behalf of the ALWP of the EBMT to compare outcomes of haploidentical, MSD, and MUD allo-HCT in patients with BCR-ABL-positive AML.

 

Methods

Adult patients with BCR-ABL-positive AML undergoing allo-HCT in first complete remission (CR1) between 2015 and 2024 reported to the EBMT were included. Overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), non-relapse mortality (NRM), GVHD, and GVHD-free, relapse-free survival (GRFS) were assessed. Multivariate Cox regression analyses were performed to identify factors associated with transplant outcomes. 

Results

A total of 159 patients were included, including 34 haploidentical HCT, 57 MSD, and 68 10/10 MUD recipients. The median age at transplantation was 48.8 years (interquartile range [IQR], 38.0–60.6). The median interval from diagnosis to allo-HCT was 4.8 months (IQR, 3.7–6.4). Minimal residual disease (MRD) status at transplantation was available for 125 patients, including 60 (48.0%) MRD-negative and 65 (52.0%) MRD-positive patients, with no significant difference among donor groups (p=0.334). Peripheral blood was the predominant stem cell source (89.9%), whereas bone marrow grafts were more frequently used in haploidentical transplantation compared with MSD and MUD transplantation (23.5% vs. 8.8% and 4.4%, respectively; p=0.0126). Myeloablative conditioning was used in 103 patients (64.8%). PTCy-based GVHD prophylaxis was predominantly used in haploidentical transplantation (82.4% vs . 12.3% in MSD and 11.8% in MUD; p<0.001).

After a median follow-up of 2.3 years, the estimated 2-year OS and LFS for the entire cohort were 74.1% (95% CI, 65.2–81.0) and 65.9% (95% CI, 57.0–73.3), respectively. The 2-year GRFS was 55.8% (95% CI, 46.5–64.0). The cumulative RI and NRM at 2 years were 22.4% (95% CI, 15.7–29.9) and 11.7% (95% CI, 6.9–17.9), respectively. Neutrophil engraftment by day 30 was achieved in 96.7% of patients. Platelet engraftment by day 30 occurred in 86.7% of patients.

Outcomes were comparable across donor groups. Two-year OS was 77.7% after haploidentical HCT, 72.2% after MSD transplantation, and 74.5% after MUD transplantation. Two-year LFS estimates were 72.9%, 58.1%, and 69.9%, respectively. The 2-year RI was 17.5%, 32.6%, and 14.7%, while NRM was 9.5%, 9.3%, and 15.4%, respectively.

The cumulative incidence of grade II–IV acute GVHD (aGVHD) at day 100 was 26.4%, including 28.1%, 30.6%, and 22.3% after haploidentical, MSD, and MUD transplantation, respectively. The 2-year cumulative incidence of chronic GVHD was 27.1%, with rates of 17.7%, 28.0%, and 32.2% , respectively.

Among 43 deceased patients, relapse/progressive disease was the leading cause of death (48.7%), followed by treatment-related mortality (33.3%).

In multivariable Cox regression analyses, donor type was not associated with differences in LFS, OS, RI, NRM, or GVHD outcomes. Female donor-to-male recipient transplantation was associated with significantly improved LFS (hazard ratio [HR], 0.32; 95% CI, 0.11–0.93; p=0.04) but an increased risk of cGVHD (HR, 2.62; 95% CI, 1.17–5.86; p=0.02). Peripheral blood grafts were associated with a lower risk of grade II–IV aGVHD compared with bone marrow grafts (HR, 0.36; 95% CI, 0.16–0.80; p=0.01). 

Conclusion

In this large  cohort of BCR-ABL-positive AML patients transplanted in CR1, haploidentical transplantation resulted in comparable LFS, OS, RI, NRM, and GVHD outcomes compared with MSD and MUD transplantation. These findings suggest improved outcomes compared with those reported in the 2018 EBMT study.

Lin Li: No relevant conflicts of interest to declare.